Redefining Immunotherapy (Ep. 4): Melanoma Treatment Strategy: Expert Perspectives

In our fourth episode of our special vodcast series, Redefining Immunotherapy: Lessons from Melanoma, our experts discuss one of the most rapidly evolving areas in melanoma care: immunotherapy treatment strategy. Drawing on decades of combined clinical experience, the panel explores how treatment paradigms are shifting from decisions around monotherapy versus combination immunotherapy, to increasingly nuanced conversations about treatment duration, rechallenge after progression and retreatment following toxicity. Led by Prof Georgina Long AO, the panel of experts deliver candid expert debate, practical insights and clinical nuance as they explore the evolving landscape of immunotherapy treatment decisions in melanoma care. The panel discusses:     when to stop immunotherapy and why less treatment may sometimes be enough how PET complete metabolic response (CMR) is influencing treatment duration decisions rechallenge strategies after progression or immune-related toxicity managing patients after ipilimumab/nivolumab toxicity the growing move from adjuvant to neoadjuvant treatment approaches. The discussion also tackles the biology behind durable immune responses, the role of surveillance imaging, and the emerging concept of “definitive immunotherapy”, highlighting how melanoma continues to lead the way in reshaping cancer care.Be sure to take a look at our earlier episodes from this series.This special edition vodcast from Melanoma Institute Australia is suitable for Medical Oncologists, Oncology Nurses and other health professionals.SPEAKERSProf Georgina Long AO - Medical Oncologist, Melanoma Institute Australia and The University of SydneyProf Alexander Menzies - Medical Oncologist, Melanoma Institute Australia and The University of SydneyA/Prof Ines Silva - Medical Oncologist, Melanoma Institute AustraliaA/Prof Matteo Carlino - Medical Oncologist, Melanoma Institute Australia and The University of SydneyPlease note that this presentation was accurate at the time of recording (April 2026) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.This special vodcast is an initiative of ⁠Melanoma Institute Australia⁠ and made possible by an unrestricted educational grant from Bristol Myers Squibb.For more practise-changing education, visit MIA's ⁠Melanoma Education Portal⁠.